---
schema_version: "secwatch.filing_event.v1"
accession: "0001703057-26-000053"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2026-08-10T11:49:17+00:00"
generated_at: "2026-08-10T11:50:20.196631+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AbCellera Phase 2 ABCL635 meets endpoints: 83% cut in hot flash frequency vs 33% placebo

## Summary
- Phase 2 met primary endpoints: 8.8 mean reduction in daily moderate/severe hot flashes vs 3.5 placebo (p<0.001) at week 4 after single 600 mg dose
- Frequency fell 83% vs 33% placebo (50% placebo-adjusted); severity down 58% vs 12% (46% adjusted, p<0.001)
- 92 postmenopausal women enrolled, 1:1 randomized; improvements in sleep and PGI-C also significant
- No serious/severe AEs or discontinuations; common AEs: headache, fatigue, injection site reaction
- Company plans Phase 3 validation; CMO Sarah Noonberg cites potential best-in-class single-dose relief

## SEC filing metadata
- accession: 0001703057-26-000053
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2026-08-10T11:49:17+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000053/0001703057-26-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000053/abcl-20260810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001703057-26-000053
- JSON: https://secwatch.observer/filing/0001703057-26-000053.json
- Plain text: https://secwatch.observer/filing/0001703057-26-000053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.